|Awarded On||August 24, 2018|
|Title||Controlling the Activity of Anticancer T Cells by Inducing Replicative Senescence|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Maksim Mamonkin|
|Cancer Sites||Leukemia, Lymphoma|
Certain cancers can be effectively treated — and even cured — by enhancing cells from a patient’s own body. Changing these specialized immune cells, called “T cells,” to enable them recognize and kill tumor cells has a number of advantages over conventional cancer drugs. For instance, T cells can easily find tumors, multiply and remain in the body until the tumor is cleared. One downside to these powerful “living drugs” is that their long-term activity in patients hard to control or even predict, which sometimes results in unwanted toxicities. For example, T cells trained to recognize leukemia cells also attack normal blood cells responsible for preventing infections, among other functions. ...